Anthracycline therapy can induce very early increase in QT dispersion and QTc prolongation

Leukemia Research

Volumn 32, Issue 6, 2008, Pages 998-999

  Pudil, R ^a   Horacek, J M ^a,b   Horackova, J ^a   Jebavy, L ^b   Vojacek, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

^b University of Defense   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; DAUNORUBICIN; IDARUBICIN; MITOXANTRONE;

ACUTE LEUKEMIA; ADULT; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HUMAN; LETTER; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QT DISPERSION; QT PROLONGATION;

ADULT; ANTHRACYCLINES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; LONG QT SYNDROME; MALE; MIDDLE AGED; PILOT PROJECTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 40749093596     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.09.020     Document Type: Letter

References (4)

1. Yeh E.T., Tong A.T., Lenihan D., et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 109 (2004) 3122-3131
2. L'Ecuyer T., Sanjeev S., Thomas R., et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol 291 3 (2006) H1273-H1280
3. Minotti G., Menna P., Salvatorelli E., Cairo G., and Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56 2 (2004) 185-229
4. Nousiainen T., Vanninen E., Rantala A., Janutunen E., and Hartikainen J. QT dispersion and late potentials during doxorubicin therapy for non-Hodgkin's lymphoma. J Intern Med 245 4 (1999) 359-364